Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 30;29(9):6245-6259.
doi: 10.3390/curroncol29090491.

Management of Acute Myeloid Leukemia: A Review for General Practitioners in Oncology

Ryan J Stubbins  1   2 , Annabel Francis  3 , Florian Kuchenbauer  1   2   4 , David Sanford  1   2
Affiliations
Review

Management of Acute Myeloid Leukemia: A Review for General Practitioners in Oncology

Ryan J Stubbins et al. Curr Oncol. .

Abstract

Acute myeloid leukemia (AML) is a hematologic malignancy that most frequently develops in older adults. Overall, AML is associated with a high mortality although advancements in genetic risk stratification and new treatments are leading to improvements in outcomes for some subgroups. In this review, we discuss an individualized approach to intensive therapy with a focus on the role of recently approved novel therapies as well as the selection of post-remission therapies for patients in first remission. We discuss the management of patients with relapsed and refractory AML, including the role of targeted treatment and allogeneic stem cell transplant. Next, we review non-intensive treatment for older and unfit AML patients including the use of azacitidine and venetoclax. Finally, we discuss the integration of palliative care in the management of patients with AML.

Keywords: acute myeloid leukemia; chemotherapy; palliative care; stem cell transplant; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

D.S. has participated on advisory boards for Novartis, Astellas, Abbvie, and Pfizer. R.J.S., F.C.K. and A.F. declare no conflict of interest.

Figures

Figure 1
Figure 1
Overview of frontline intensive treatment of AML.
See this image and copyright information in PMC

References

    1. Stubbins R.J., Stamenkovic M., Roy C., Rodrigo J., Chung S., Kuchenbauer F.C., Hay K.A., White J., Abou Mourad Y., Power M.M., et al. Incidence and socioeconomic factors in older adults with acute myeloid leukaemia: Real-world outcomes from a population-based cohort. Eur. J. Haematol. 2022;108:437–445. doi: 10.1111/ejh.13752. - DOI - PubMed
    1. Cancer Stat Facts: Leukemia—Acute Myeloid Leukemia (AML) [(accessed on 18 May 2022)]; Available online: https://seer.cancer.gov/statfacts/html/amyl.html.
    1. Canadian Cancer Statistics Advisory Commitee Canadian Cancer Statistics. 2019. [(accessed on 18 May 2022)]. Available online: cancer.ca/Canadian-Cancer-Statistics-2019-EN.
    1. Siegal T., Benouaich-Amiel A., Bairey O. Neurologic complications of acute myeloid leukemia. Diagnostic approach and therapeutic modalities. Blood Rev. 2021;53:100910. doi: 10.1016/j.blre.2021.100910. - DOI - PubMed
    1. Khoury J.D., Solary E., Abla O., Akkari Y., Alaggio R., Apperley J.F., Bejar R., Berti E., Busque L., Chan J.K.C., et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36:1703–1719. doi: 10.1038/s41375-022-01613-1. - DOI - PMC - PubMed